Drug distributor McKesson and private equity firm Clayton Dubilier & Rice agreed Tuesday to take Option Care Health private in a $5.8 billion transaction, combining strategic supplier and financial sponsor capital to control the largest independent home infusion provider in the United States. The deal values Option Care at a premium reflecting margin certainty in a sector where reimbursement complexity drives consolidation toward scaled operators.
Option Care manages infusion therapy for chronic conditions including immune deficiencies, cancer, and infections, serving roughly 200,000 patients annually through a network of 100-plus pharmacies. McKesson already supplies specialty pharmaceuticals to Option Care under existing commercial agreements. The acquisition converts a customer relationship into vertical integration, capturing dispensing economics and data visibility across the infusion supply chain. CD&R brings buyout structuring and operational re-engineering expertise, suggesting the buyers see margin expansion through procurement leverage, regional densification, and nurse productivity.
The transaction matters because home infusion sits at the intersection of three healthcare trends: cost migration from hospitals to lower-acuity settings, specialty drug growth outpacing traditional pharmacy, and payer pressure to standardize high-complexity therapies. Option Care's scale creates negotiating power with insurers and pharmaceutical manufacturers, while McKesson gains exposure to site-of-care economics beyond hospital distribution. The joint ownership structure—McKesson as strategic partner, CD&R as governance lead—suggests the business will be run for cash generation and tuck-in acquisitions rather than another public-market exit. That positioning is rational; home infusion consolidation still fragments across regional operators, and the top three providers control less than half the addressable market.
Allocators should watch for secondary compression in remaining public specialty pharmacy names, particularly Cencora and Cardinal Health, both of which have expressed interest in alternate-site exposure. The deal also pressures regional infusion providers to either scale through M&A or accept strategic buyer offers at lower multiples. McKesson's move signals that distribution giants view direct patient-service assets as defensive infrastructure, not optionality. Shareholder approval for Option Care is expected in Q4 2025, with deal close contingent on antitrust clearance from the FTC, which has recently scrutinized vertical integration in pharmaceutical supply chains.
The $5.8 billion price paid for a business generating mid-single-digit EBITDA margins tells you home infusion is now categorized as essential plumbing, not speculative therapeutics.
The takeaway
$5.8B private take-out by distributor plus PE firm locks infusion economics and forces regional consolidation across specialty pharmacy.
Editorial & Disclosure Notice: This article was written with artificial intelligence from public sources and is published without individual human review. Artificial intelligence and other digital tools are also used for research, analysis, editing, formatting, and production. Errors, omissions, outdated information, or inaccuracies may occur. References to companies, brands, products, services, organizations, or individuals are for informational and editorial purposes and do not imply endorsement, sponsorship, affiliation, partnership, or approval unless expressly stated. All trademarks and other intellectual property remain the property of their respective owners. Opinions, analysis, estimates, and commentary are informational only and should not be construed as financial, investment, legal, tax, medical, procurement, or other professional advice. Information may be corrected, clarified, or updated after publication. Corrections or removal requests: jenny@pops4.com.
Want the 60-second program for your specific event?
Enter your event and email — we build it and send the branded proposal before lunch. No obligation.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.